These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

111 related articles for article (PubMed ID: 3273254)

  • 1. [Pigmentary changes of the retina in dialysis patients treated with deferoxamine].
    Mathys B; Baeck A; Verougstraete C; Verstappen A; D'Haene M; Zanen A
    Bull Soc Belge Ophtalmol; 1988; 229():49-60. PubMed ID: 3273254
    [No Abstract]   [Full Text] [Related]  

  • 2. [Indications for desferrioxamine in patients with chronic renal insufficiency treated by dialysis].
    Simon P
    Nephrologie; 1986; 7(5):177-80. PubMed ID: 3822038
    [No Abstract]   [Full Text] [Related]  

  • 3. [Poisoning of retinal pigment epithelium by deferoxamine. A case report].
    Charton N; Sahel JA; Flament J
    Bull Soc Ophtalmol Fr; 1990; 90(6-7):599-602. PubMed ID: 2225255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Ocular side effects of deferoxamine therapy in aplastic anemia with transfusion-induced hemochromatosis].
    Spraul CW; Schicketanz C; Lang GE
    Klin Monbl Augenheilkd; 1996 Jul; 209(1):31-6. PubMed ID: 8965474
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Disseminated mucormycosis in a hemodialyzed female patient treated with deferoxamine].
    Ponz E; Campistol JM; Ribalta T; Montoliú J; Ramírez J; Almirall J; Revert L
    Rev Clin Esp; 1991 Feb; 188(2):85-7. PubMed ID: 2041907
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Severe ocular toxicity of desferrioxamine in the hemodialyzed patient].
    Bournerias F; Monnier N; Dufier JL; Réveillaud RJ
    Nephrologie; 1987; 8(1):27-9. PubMed ID: 3587485
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Successful treatment of progressive dialysis encephalopathy. Case report].
    Weiland P; Köhler M; Glatzel E
    Z Urol Nephrol; 1985 Jul; 78(7):387-93. PubMed ID: 4050157
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Dialysis bone disease associated with other factors].
    Nakazawa R
    Nihon Rinsho; 1992 Jan; 50 Suppl():789-95. PubMed ID: 1578768
    [No Abstract]   [Full Text] [Related]  

  • 9. [Effect of deferoxamine on erythropoiesis in patients hemodialyzed for chronic renal insufficiency treated with erythropoietin].
    Kalinowski M; Popławski A; Kaliszewski Z; Juzwiuk J
    Pol Merkur Lekarski; 1996 Oct; 1(4):232-4. PubMed ID: 9156931
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aluminum kinetics of the REDY system: a study of the impact of deferoxamine therapy.
    Culpepper CP; Cummings R; Westervelt FB; Savory J; Wills MR
    Trans Am Soc Artif Intern Organs; 1983; 29():76-80. PubMed ID: 6673321
    [No Abstract]   [Full Text] [Related]  

  • 11. Role of desferrioxamine in the treatment of dialysis encephalopathy.
    Ackrill P; Ralston AJ; Day JP
    Kidney Int Suppl; 1986 Feb; 18():S104-7. PubMed ID: 3457985
    [No Abstract]   [Full Text] [Related]  

  • 12. The role of desferrioxamine in dialysis-associated mucormycosis: report of three cases and review of the literature.
    Boelaert JR; van Roost GF; Vergauwe PL; Verbanck JJ; de Vroey C; Segaert MF
    Clin Nephrol; 1988 May; 29(5):261-6. PubMed ID: 3293856
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in bone histology after treatment with desferrioxamine.
    Ott SM; Andress DL; Nebeker HG; Milliner DS; Maloney NA; Coburn JW; Sherrard DJ
    Kidney Int Suppl; 1986 Feb; 18():S108-13. PubMed ID: 3457986
    [No Abstract]   [Full Text] [Related]  

  • 14. Encephalopathy in chronic renal failure responsive to deferoxamine therapy. Another manifestation of aluminum neurotoxicity.
    Sprague SM; Corwin HL; Wilson RS; Mayor GH; Tanner CM
    Arch Intern Med; 1986 Oct; 146(10):2063-4. PubMed ID: 3767553
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma aluminum and iron kinetics in hemodialyzed patients after i.v. infusion of desferrioxamine.
    Ciancioni C; Poignet JL; Mauras Y; Panthier G; Delons S; Allain P; Man NK
    Trans Am Soc Artif Intern Organs; 1984; 30():479-82. PubMed ID: 6533925
    [No Abstract]   [Full Text] [Related]  

  • 16. Precipitation of dialysis dementia by deferoxamine treatment of aluminum-related bone disease.
    Sherrard DJ; Walker JV; Boykin JL
    Am J Kidney Dis; 1988 Aug; 12(2):126-30. PubMed ID: 3400633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Retinal oscillatory potentials in the study of retinopathy in dialyzed subjects with chronic renal insufficiency].
    Lazzarino LG; De Grandis D; Pitzorno F; Polo A
    Riv Neurol; 1990; 60(3):103-7. PubMed ID: 2084813
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Iron-overload in patients on maintenance hemodialysis: diagnostic criteria, indications and treatment by desferrioxamine (author's transl)].
    Simon P; Bonn F; Guezennec M; Tanquerel T; Ksang
    Nephrologie; 1981; 2(4):165-70. PubMed ID: 7329501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Severe Yersinia enterocolitica infections in kidney failure patients under dialysis].
    Cabanne JF; Dubot P
    Presse Med; 1991 Nov; 20(38):1905. PubMed ID: 1836634
    [No Abstract]   [Full Text] [Related]  

  • 20. Irreversible ocular toxicity from single "challenge" dose of deferoxamine.
    Bene C; Manzler A; Bene D; Kranias G
    Clin Nephrol; 1989 Jan; 31(1):45-8. PubMed ID: 2783668
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.